Aarti Pharmalabs Limited has made a regulatory disclosure to BSE Limited and the National Stock Exchange of India Limited regarding the allotment of equity shares under its employee stock option plan.
The Nomination and Remuneration Committee of the Board of Directors, through a resolution by circulation, approved the allotment of 22,062 equity shares of face value ₹5 each. This allotment was made pursuant to the exercise of stock options by eligible employees under the Aarti Pharma Performance Stock Option Plan 2023 (PSOP 2023).
The allotment was conducted in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The newly allotted equity shares will rank pari-passu in all respects with the existing equity shares of the company.
Following this allotment, the company's paid-up equity share capital has increased to ₹45,33,99,065 (Forty-five crore thirty-three lakhs ninety-nine thousand and sixty-five Only), representing 9,06,79,813 (Nine crore, six lakhs, seventy-nine thousand eight hundred and thirteen Only) fully paid-up equity shares of face value ₹5 each.
The disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The letter was signed by Jeevan Mondkar, Company Secretary and Legal Head (ICSI Membership No. A22565).